G1 Therapeutics, Inc. Banner Image

G1 Therapeutics, Inc. has reached its limit for free report views

Work for G1 Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

G1 Therapeutics, Inc.

  • Ticker GTHX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
G1 Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Research Triangle Park, North Carolina
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; rintodestrantMore is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.
G1 Therapeutics, Inc.

Most Recent Annual Report

G1 Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. G1 Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports